They also suggest that aberrant DDR1 signalling may contribute to the high level of Wnt oncogenic activity observed in some mCRC and predict that combinations of nilotinib with agents targeting the Wnt/β ‐catenin pathway may be effective against these tumours. The gene discussed is DDR1; the disease is neoplasm.